



IN CONFIDENCE

Client
Address

16th September 2013

Differential Expression by iTRAQ analysis Report IQ130916PIAL_template

SAMPLES

PI reference:
Date of receive:
Number of samples:
Source of sample:
Service required: Differential Expression by iTRAQ analysis

METHODS

The protein samples were acetone precipitated, reduced, alkylated and trypsin digested according to the iTRAQ protocol (Applied Biosystems). Samples were then labeled using the iTRAQ reagents as follow:

Sample name	iTRAQ reagent
1	114
2	115
3	116
4	117

Peptides were desalted on a Strata-X 33 μ m polymeric reversed phase column (Phenomenex) and dissolved in a buffer containing 10mM KH₂PO₄ pH3 in 10% acetonitrile before separation by strong cation exchange liquid chromatography (SCX) on an Agilent 1100 HPLC system using a PolySulfoethyl column (4.6 x 100 mm, 5 μ m, 300 A). Peptides were eluted with a linear gradient of 0-400 mM KCl. Eight fractions containing the peptides were collected and after desalting on Strata-X columns were loaded onto a Agilent Zorbax 300SB-C18, 3.5 μ m (Agilent Technologies) running on an Shimadzu Prominence nano HPLC system [Shimadzu]. Peptides were resolved with a gradient of 10-40% acetonitrile (0.1% trifluoroacetic acid) over 160 minutes and analysed on a 5600 TripleTOF mass spectrometer [AB Sciex].



DATA ANALYSIS

Spectral data were analysed against the Swiss-Prot database using ProteinPilot™ 4.0 Software (AB Sciex) and taxonomy set to XXXX. The database was downloaded date and contained XXXXX sequences.

Accredited for compliance with ISO/IEC 17025, NATA accredited list of SOP's:

0_11 Sample Prep for iTRAQ¹

3_01 HPLC Agilent²

0_12 Solid Phase Extraction¹

3_05 HPLC Cation Exchange²

8_04 Protein Pilot²

SOPs carried out at Proteomics International Facility, located at ¹Bayliss Building, UWA campus, Crawley, Australia and ²MRF Building, 50 Murray Street, Perth, Australia.

RESULTS

The results provided relate only to the samples as listed in table above.

A summary of the results is shown below.

Features	Value
No. of proteins identified	XXX
Global FDR	XXX
Local FDR	XXX
Number of MS/MS spectra used	XXX
Confidence level of protein detection	XXX
Unused ProtScore cut off	XXX
No. of differentially expressed proteins	
115 :114	XXX
117:114	XXX
116:114	XXX

The full report with details of the identified proteins is shown in the attached spreadsheet.

IQ130916PIAL iTRAQ ProteinPilot summary (report template).xlsx

NOTES ON INTERPRETING THE RESULTS

Unused (ProtScore)

A measure of the protein confidence for a detected protein, calculated from the peptide confidence for peptides from spectra that have not already been completely used by higher scoring winning proteins. For 95% confidence, the required Unused ProtScore is 1.3.

Total (ProtScore)

A measure of the total amount of evidence for a detected protein. The Total ProtScore is calculated using all of the peptides detected for the protein. The Total ProtScore does **not** indicate the percent confidence for the identification of a protein.

% Cov (Coverage)

The percentage of matching amino acids from identified peptides divided by the total number of amino acids in the sequence.



Ratio

The average ratio for the protein, relative to 114.

The p-value

For each protein ratio reported the program calculates a p-value to help you assess whether changes in protein expression are real or not.

The p-value reports the probability that the null hypothesis (that is, the observed value is different from unity by chance) is true. P-values range from 0 to 1. A p-value of less than or equal to 0.05 indicates statistically significant differential expression and is highlighted in your results.

False discovery rate (FDR)

The FDR was automatically calculated by the Proteomics System Performance Evaluation Pipeline (PSPEP) feature in the ProteinPilot™ software using the reversed version of the protein sequences contained in the search database. The software calculates both a local and a global FDR.

The local FDR estimates the “local” error rate around a given identification, which indicates the likelihood that the specific identification is incorrect.

The global FDR estimates the error rate of the whole “global” set of answers defined by a threshold value. That is, the global FDR estimates the likely error rate of the entire set of identifications with scores as good as or better than the threshold.

With Compliments

Proteomics International

Authorised Signatory's name
Andreja Livk
Contract Services Manager

This report should not be reproduced except in full written approval of Proteomics International.
All reports are supplied subject to Proteomics International's standard terms and conditions, available at <http://www.proteomics.com.au/TermsAndConditions.aspx>

Particular attention is drawn to clause 8:
LIABILITY & INDEMNITY

(a) Proteomics International (PI) shall not be subject to nor incur, and the Customer hereby releases PI from, any claim, action or liability for consequential loss or damage to persons or property including, without limiting the generality of the foregoing, loss of use of the Goods or services or loss of profits or loss on resale arising by reason of delays, non-delivery, defective materials or workmanship, negligence or any act, matter, conduct or thing done, permitted or omitted by PI.

(b) PI and the Customer hereby agree that, to the extent permitted by law, in the event of any loss, damage or claim arising out of a breach of one or more of the warranties pursuant to these Terms and Conditions, the liability of PI (if applicable) is limited to the replacement of the goods or the cost of replacement or, in the case of a service, the cost of supply or re-supply of the service.





(c) The Customer's property under PI's custody or control will be entirely at the Purchaser's risk as regards loss or damage thereto or from whatsoever cause arising.

(d) The Customer shall comply with all instructions of PI in relation to the handling, storage, sale and the use of the goods. Notwithstanding such compliance, the Customer shall keep PI indemnified against all costs, claims, demands, expenses and liabilities of whatsoever nature, including without limitation, claims for death, personal injury, damage to property and consequential loss (including loss of profit) which may be made against PI or which PI may sustain, pay or incur as a result of or in connection with the manufacture, demand, expense or liability that shall be directly and solely attributable to any breach of contract by, or negligence of, PI or a duly authorised employee of PI.

(e) All products and services are sold for research use only, and are not for human or drug use and should not be relied upon for the purposes of clinical trial. PI is not liable and the customer agrees to indemnify PI for any loss or expense for all claims or proceedings made or instituted against the customer of PI arising out of the application or the use of the goods or services other than for in-vitro research purposes. The customer acknowledges that it does not rely upon the skill and judgement of PI as to the suitability of its products or results provided for the purposes of the customer.

